Status:
UNKNOWN
Repetitive Transcranial Magnetic Stimulation in Early Psychosis and The Functional Connectivity Biotypes
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Collaborating Sponsors:
Suzhou Psychiatric Hospital
Guangzhou Psychiatric Hospital
Conditions:
Schizophrenia; Psychosis
First Episode Psychosis
Eligibility:
All Genders
14-45 years
Phase:
NA
Brief Summary
The present study plans to explore different cortical targets of repetitive transcranial magnetic stimulation (rTMS) for populations at the early phase of psychosis, including those at clinical high r...
Detailed Description
Schizophrenia is a life long illness, the management of its early stage is the key in its long term outcomes. The early stage of schizophrenia includes the prodromal and first episode, during which th...
Eligibility Criteria
Inclusion
- For subjects at clinical high-risk for psychosis
- Meeting the syndrome of clinical high risk of psychosis, identified by a face-to-face interview using the Chinese version of Structured Interview for Prodromal Syndromes / Scale of Prodromal Symptoms (SIPS/SOPS);
- Given the written consent for participation.
- Age between 14-45 years old;
- IQ\>69;
- PANSS total scores \>= 55 or BVMT-R score \<= 26;
Exclusion
- any contraindication to TMS treatment or magnetic resonance imaging (MRI)
- substance or alcohol abuse within recent three months
- any sensorimotor disorder (e.g., hearing disorder, lose one's sight), or any neurological disease (brain injury, epilepsy ) or any other physical disease which may lead to psychotic symptoms.
- For subjects with first-episode schizophrenia
- Inclusion Criteria:
- Meeting the DSM-V diagnostic criteria for schizophrenia spectrum disorders;
- Given the written consent for participation.
- Age between 14-45 years old;
- IQ\>69;
- during the first episode without a full remission;
- PANSS total scores \>= 55 or BVMT-R score \<= 26;
- within receiving rTMS, patients can receive second-generation antipsychotics except clozapine with stable dosages
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04853485
Start Date
August 1 2020
End Date
December 31 2024
Last Update
December 29 2023
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
The Affiliated Brain Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
2
Nantong Fourth People's Hospital & Nantong Brain Hospital
Nantong, Jiangsu, China, 226000
3
Suzhou Guangji Hospital
Suzhou, Jiangsu, China
4
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China, 200030